Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine BiopharmaSBFMW 34 EV-to-EBIT is 0.00 as of Sep. 09, 2026. GuruFocus rates SBFMW with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 682 Drug Manufacturers companies, Sunshine Biopharma ranks better than 95.31% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sunshine Biopharma's Enterprise Value for the quarter that ended in Jun. 2026 was $0.00 Mil.
Sunshine Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma EV-to-EBIT Related Terms
Sunshine Biopharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's EV-to-EBIT falls into.
Sunshine Biopharma's current Enterprise Value is $0.00 Mil.
Sunshine Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (SBFMW) has a EV-to-EBIT of 0.00 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sunshine Biopharma and its competitors. According to the industry distribution chart, Sunshine Biopharma ranks #32 out of 682 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is Sunshine Biopharma's EV-to-EBIT too high?
Sunshine Biopharma's current EV-to-EBIT is 0.00. Based on the distribution chart, Sunshine Biopharma ranks #32 out of 682 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's EV-to-EBIT compare to BUDZ and CVSI?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #32 out of 682 companies for EV-to-EBIT. This places Sunshine Biopharma in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.11, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sunshine Biopharma and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Sunshine Biopharma (SBFMW) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sunshine Biopharma (SBFMW), the current EV-to-EBIT is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFMW
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFMW has been successfully added to your 
